A modified approach to induce predictable congestive heart failure by volume overload in rats.
The model of infrarenal aortocaval fistula (ACF) has recently gained new interest in its use to investigate cardiac pathophysiology. Since in previous investigations the development of congestive heart failure (CHF) was inconsistent and started to develop earliest 8-10 weeks after fistula induction using a 18G needle, this project aimed to induce a predictable degree of CHF within a definite time period using a modified approach. An aortocaval fistula was induced in male Wistar rats using a 16G needle as a modification of the former 18G needle-technique described by Garcia and Diebold. Results revealed within 28 ± 2 days of ACF significantly increased heart and lung weight indices in the ACF group accompanied by elevated filling pressure. All hemodynamic parameters derived from a pressure-volume conductance-catheter in vivo were significantly altered in the ACF consistent with severe systolic and diastolic left ventricular dysfunction. This was accompanied by systemic neurohumoral activation as demonstrated by elevated rBNP-45 plasma concentrations in every rat of the ACF group. Furthermore, the restriction in overall cardiac function was associated with a β1- and β2-adrenoreceptor mRNA downregulation in the left ventricle. In contrast, β3-adrenoreceptor mRNA was upregulated. Finally, electron microscopy of the left ventricle of rats in the ACF group showed signs of progressive subcellular myocardial fragmentation. In conclusion, the morphometric, hemodynamic and neurohumoral characterization of the modified approach revealed predictable and consistent signs of congestive heart failure within 28 ± 2 days. Therefore, this modified approach might facilitate the examination of various questions specific to CHF and allow for pharmacological interventions to determine pathophysiological pathways.
Department of Anesthesiology and Intensive Care Medicine, Campus Charité, Mitte and Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Sascha
S
Treskatsch
Department of Anesthesiology and Intensive Care Medicine, Campus Charité, Mitte and Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Aarne
A
Feldheiser
Department of Anesthesiology and Intensive Care Medicine, Campus Charité, Mitte and Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Adrian T
AT
Rosin
Department of Anesthesiology and Intensive Care Medicine, Campus Charité, Mitte and Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Marco
M
Sifringer
Institute of Physiology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Helmut
H
Habazettl
Department of Anesthesiology and Intensive Care Medicine, Campus Charité, Mitte and Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Shaaban A
SA
Mousa
Institute of Anatomy, Ludwig-Maximilians-Universität München, München, Germany.
Mehdi
M
Shakibaei
Department of Anesthesiology and Intensive Care Medicine, Campus Charité, Mitte and Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Michael
M
Schäfer
Department of Anesthesiology and Intensive Care Medicine, Campus Charité, Mitte and Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Claudia D
CD
Spies
D000818:Animals; D004195:Disease Models, Animal; D006333:Heart Failure / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009419:Nerve Tissue Proteins / Q000097:blood; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D018342:Receptors, Adrenergic, beta-1 / Q000096:biosynthesis; D018343:Receptors, Adrenergic, beta-2 / Q000096:biosynthesis; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000378:metabolism / Q000503:physiopathology
D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D018342:Receptors, Adrenergic, beta-1; D018343:Receptors, Adrenergic, beta-2; C073021:brain natriuretic peptide-45